We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

59 hedge funds and large institutions have $62.7M invested in Viridian Therapeutics in 2018 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 7

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

16% more funds holding

Funds holding: 51 → 59 (+8)

4% more capital invested

Capital invested by funds: $60M → $62.7M (+$2.66M)

0.26% more ownership

Funds ownership: 1.72% → 1.98% (+0.26%)

Holders
59
Holders Change
+8
Holders Change %
+15.69%
% of All Funds
1.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
24
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.75M
2
6CM
683 Capital Management
New York
+$3.62M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.96M
4
AG
Artal Group
Luxembourg
+$2.9M
5
BlackRock
BlackRock
New York
+$1.7M

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$541K
2
Renaissance Technologies
Renaissance Technologies
New York
-$371K
3
OAM
Oxford Asset Management
United Kingdom
-$321K
4
VCA
Verdence Capital Advisors
Maryland
-$294K
5
BWP
BSW Wealth Partners
Colorado
-$232K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$17K +$16K +147 +1,838%
SEI Investments
52
SEI Investments
Pennsylvania
$10K +$10.1K +93 New
AIP
53
Ameritas Investment Partners
Nebraska
$8K +$8.04K +74 New
US Bancorp
54
US Bancorp
Minnesota
$7K – – –
LTFS
55
Ladenburg Thalmann Financial Services
Florida
$5K +$5.11K +47 New
KCPG
56
Kavar Capital Partners Group
Kansas
$4K +$4.35K +40 New
IWM
57
IHT Wealth Management
Illinois
$1K – – –
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
$1K – – –
MAM
59
Meeder Asset Management
Ohio
$1K +$978 +9 New
VF
60
Virtu Financial
New York
– -$541K -3,460 Closed
OAM
61
Oxford Asset Management
United Kingdom
– -$321K -2,052 Closed
VCA
62
Verdence Capital Advisors
Maryland
– -$294K -1,879 Closed
BWP
63
BSW Wealth Partners
Colorado
– -$232K -1,482 Closed
Parallax Volatility Advisers
64
Parallax Volatility Advisers
California
– -$20K -126 Closed
DCM
65
Delpha Capital Management
New York
– -$4K -24 Closed
TCM
66
Tradewinds Capital Management
Washington
– -$2K -13 Closed
1 2
3

VRDN Hedge Fund Activity: Q1 2018 in Review

59 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2018, worth a combined $62.7M — up 4.4% from $60M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new VRDN positions and 7 closed out — a net gain of 9 holders — while 24 added to existing stakes and 7 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $8.75M. The largest seller was Virtu Financial, exiting entirely with an estimated $541K sold.

  • 59 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2018, up from 51 in Q4 2017.
  • Funds reported $62.7M of Viridian Therapeutics stock for Q1 2018, up 4.4% quarter-over-quarter.
  • 16 funds opened new Viridian Therapeutics positions in Q1 2018 and 7 closed out, a net change of +9 holders.
  • The largest Viridian Therapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $8.75M added.
  • The largest Viridian Therapeutics seller in Q1 2018 was Virtu Financial, an estimated $541K sold.

Based on aggregated 13F filings for Q1 2018.